On May 12, 2022 Novartis reported that highlights data from across its oncology portfolio at the upcoming 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and the European Hematology Association (EHA) (Free EHA Whitepaper) 2022 Hybrid Congress (Press release, Novartis, MAY 12, 2022, View Source [SID1234614412]). With nearly 130 abstracts from Novartis-sponsored and investigator-initiated trials accepted, the data showcase research across over 20 compounds in key disease areas, including breast, lung and prostate cancers, leukemia, lymphoma, multiple myeloma and other blood disorders.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to push the boundaries of science with advanced therapies and novel combinations to help address the individual needs of patients," said Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, Novartis. "We are particularly excited about the latest data on CDK recycling with Kisqali, and first results for Tafinlar + Mekinist in a rare pediatric brain cancer."

Key highlights of data accepted by ASCO (Free ASCO Whitepaper):

Medicine Abstract Title Abstract Number/ Presentation Details
Kisqali (ribociclib)*

A randomized phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor positive (HR+), HER2 negative metastatic breast cancer (MBC): MAINTAIN trial† Abstract # LBA1004
Oral Presentation:
Saturday, June 4, 1:15 PM – 4:15 PM CDT

Kisqali (ribociclib)* Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML)-2 Abstract #1017
Poster Discussion:
Monday, June 6, 8:00 AM – 11:00 AM CDT
Kisqali (ribociclib)*

Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) vs abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor–positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC) Abstract #1015
Poster Discussion:
Monday, June 6, 8:00 AM – 11:00 AM CDT

Piqray (alpelisib) Alpelisib (ALP) + Fulvestrant (FUL) in Patients (pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2−), Advanced Breast Cancer (ABC): Biomarker (BM) Analyses by Next-Generation Sequencing (NGS) From the SOLAR-1 Study Abstract #1006
Oral Presentation:
Saturday, June 4, 1:15 PM – 4:15 PM CDT
Piqray (alpelisib)

Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study Abstract #1018
Poster Discussion:
Monday, June 6, 8:00 AM – 11:00 AM CDT

Scemblix (asciminib) Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): wk 96 update Abstract #7004
Oral Presentation:
Tuesday, June 7, 9:45 AM – 12:45 PM CDT
Tafinlar (dabrafenib) / Mekinist (trametinib) Primary analysis of a phase II trial of dabrafenib + trametinib (dab + tram) in BRAF V600–mutant pediatric low-grade glioma (pLGG) Abstract #2002
Oral Presentation:
Monday, June 6, 11:30 AM – 2:30 PM CDT
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) 177Lu-PSMA-617 in PSMA-positive metastatic castration-resistant prostate cancer: prior and concomitant treatment subgroup analyses of the VISION trial

Abstract #5001
Oral Presentation:
Sunday, June 5, 8:00 AM – 11:00 AM CDT

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Tolerability of 177Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): a VISION study subgroup analysis Abstract #5047
Poster available:
Monday, June 6, 1:15 PM – 4:15 PM CDT
Locametz (kit for the preparation of gallium Ga 68 gozetotide injection)** 68Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to 177Lu-PSMA-617 in patients with mCRPC: a VISION sub-study Abstract #5002
Oral Presentation:
Sunday, June 5, 8:00 AM – 11:00 AM CDT
Lutathera (lutetium Lu 177 dotatate)*** Effectiveness and safety of re-treatment with lutetium Lu 177 dotatate in patients with progressive neuroendocrine tumors in the United States: a retrospective real-world study Abstract #e16215

Key highlights of data accepted by EHA (Free EHA Whitepaper):

Medicine Abstract Title Abstract Number/ Presentation Details
Scemblix (asciminib) Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: week 96 update Abstract #S155
Oral Presentation:
Sunday, June 12, 11:30 AM – 12:45 PM CEST
Scemblix (asciminib) Asciminib provides durable molecular responses in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: Updated efficacy and safety data from a Phase 1 trial Abstract #P704
Poster Available:
Friday, June 10, 4:30 PM – 5:45 PM CEST
Kymriah
(tisagenlecleucel) Tisagenlecleucel in pediatric and young adult patients (Pts) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Final analyses from the ELIANA study Abstract #S112
Oral Presentation:
Sunday, June 12, 11:30 AM – 12:45 PM CEST

YTB323 Phase I study of YTB323, a chimeric antigen receptor (CAR)-T cell therapy manufactured using T-Charge, in patients with relapsed/refractory diffuse large B-cell lymphoma Abstract #S212
Oral Presentation:
Saturday, June 11, 11:30 AM – 12:45 PM CEST
PHE885 Phase I study data update of PHE885, a fully human BCMA-directed CAR-T cell therapy manufactured using the T-Charge platform for patients with relapsed/refractory (R/R) multiple myeloma (MM) Abstract #P1446
Poster Available:
Friday, June 10, 4:30 PM – 5:45 PM CEST
Sabatolimab First results of a Phase II study (STIMULUS-AML1) investigating sabatolimab + azacitidine + venetoclax in patients with newly diagnosed acute myeloid leukemia Abstract #P582
Poster available:
Friday, June 10, 4:30 PM – 5:45 PM CEST

Promacta/Revolade
(eltrombopag) Sustained response off treatment in eltrombopag-treated patients with ITP who are refractory or relapsed after first-line steroids: primary analysis of the phase II TAPER trial Abstract #S292
Oral Presentation
Saturday, June 11, 11:30 AM – 12:45 PM CEST
Product Information
For full prescribing information, including approved indications and important safety information about marketed products, please visit View Source